News

1 2 3 4 5 6 11 16 21
NEWS

SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics

  • SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts. 
  • Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies. 
  • Lead program expected to initiate first clinical studies in 2021.
  • Rights to BOXR platform acquired for total of $11.5 million, including $8.1 million upfront and potential $3.4 million in milestones.

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that it has acquired the rights to Unum Therapeutics’ (Nasdaq: UMRX) BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors. The proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment. 

NEWS

SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the ongoing Phase 1/1b study of IL-15 superagonist, SO-C101, for the treatment of patients with advanced/metastatic solid tumors. Part B will examine SO-C101 in combination with PD-1 inhibitor pembrolizumab. The trial is conducted in partnership with Cytune Pharma.

NEWS

SOTIO Appoints Richard Sachse as Chief Medical Officer

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer effective July 1, 2020. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and scientist and was most recently the deputy Chief Medical Officer of SOTIO.